News
Menu
- Home
- Company
- Products
- Technology
- Investors
-
News
-
Latest News
- 8mg Higher Dose SCIB1 Study On Track
- Moditope Patent Published
- SCIB1 Granted FDA Orphan Drug Status
- Nottingham Technology Grant
- ImmunoBody technology used in prostate cancer protein discovery
- DNA ImmunoBody Patent Granted in Japan
- New data for SCIB1 in metastatic melanoma
- Extension to Ichor Option and Issue of Equity
- Notice of AGM
- Investor update showcases Moditope® platform and updates SCIB1 trial progress
- Investor Day Agenda
- Investor Day
- DNA IB Patent in Australia
- Frankfurt Listing
- SCIB1 8mg Study Update
- Scancell welcomes new study in The Journal of Clinical Investigation
- ImmunoBody Patent Approved for Grant in Japan
- Update on patient recruitment in the ongoing SCIB1 clinical trial
- SCIB1 Trial Update – Higher Dose Allowed in Phase 1/2 Trial
- Update on SCIB1 Phase 1/2 clinical trial
- Stimulation of killer CD4 T cells with potent anti-tumour activity
- SCIB Trial Update - Approval to dose patients for up to 5 years
- SCIB1: First patient treated in Phase II clinical trial
- SCIB1 Trial Update
- Holdings in Company
- Investor presentation 2012
- ImmunoBody® Patent Approved in US
- Helium Special Situations increases interest in Scancell
- Confirmation of second tranche payment of £2.85 million from Arana Therapeutics
- Progress on possible second tranche payment from Arana Therapeutics
- SCIB1: Patent Awarded
- SCIB1: Safety Review and Dose Escalation
- Scancell develops new vaccine for the treatment of lung cancer
- Change of Board Structure
- SCIB1: Safety Review and Dose Escalation 2011
- Re: SCIB1 Clinical Trial Patient Recruitment
- Collaboration With ImmuneRegen BioSciences® Yields Positive Results in Cancer Vaccine Studies
- Appointment of COO
- Antibody Licence Agreement with Cancer Research Technology
- Withdrawal from PLUS and Admission to AIM
- Research collaboration with immatics to develop novel ImmunoBody® vaccines for colorectal cancer
- SCIB1 Phase I Trial Commences
- Scancell Enters Strategic Collaboration with ImmuneRegen BioSciences®
- National Institutes of Health Licensing Agreement
- Clinical Trial Approval for SCIB1 melanoma vaccine study
- Scancell Selects PharmaNet Development Group for SCIB1 Clinical Trial
- Completion of GMP manufacture for Scancell’s SCIB1 Clinical Trial
- Scancell Partners With ImmunoVaccine Technologies to Advance DNA Vaccine Delivery
- Scancell licenses TriGrid™ electroporation device from Ichor Medical Systems
- Scancell licenses key ImmunoBody® patents from Merck Serono
- Scancell Receives GBP250,000 emda Grant
- GMP Manufacture Deal With Cobra
- Admission to PLUS and Start of Trading
- Reports and accounts April 2008
- Scancell sells antibody pipeline to Peptech
- GTC Biotherapeutics and Scancell Collaborate on SC101 Antibody
- Scancell Raises £1.0 Million In Rights Issue
- Scancell Signs New Agreement with Biovation to DeImmunise SC101
- Scancell Secures Exclusive Worldwide Licence Agreement
- Scancell Raises £1.3 Million ($2.34M; €2M) in New Funding Round
- Scancell Appoints Dr Michael Capaldi as CEO
- Scancell, Onyvax and CRT Announce Agreement to Facilitate the Development of "ImmunoBody"
- Scancell and Celltech Announce that they will Collaborate on the Development of Novel Monoclonal
- Scancell and Isu Chemical Announce Collaboration and Licensing Agreement for Scancell's Antibody
- Genmab and Scancell Announce Cancer Antibody Product Collaboration — First Disease Target Identified
- Advances in Cancer Research Webinar
- Collaboration with Karolinska
- Scancell’s SCIB1 ImmunoBody® cancer vaccine being presented at the World Vaccine Congress
- Citrullination – linking cancer and autoimmunity?
- Scancell to present at the 23rd Annual NewsMakers in the Biotech Industry Conference in NYC
- Europe Patent Release
- Commentary: Richard Goodfellow. Why we want to work with patient advocacy groups
- Webcasts, Interviews and Media Coverage
- Archived Webcasts and Interviews
-
Latest News
-
News
- Latest News
- Webcasts, Interviews and Media Coverage
-
Regulatory news
- Interim Results for the six months ended 31 October 2014
- Scancell to provide positive SCIB1 Phase 1/2 clinical trial update during corporate presentations
- Holdings in Company - 15th December 2014
- Change of Registered Office
- Results of AGM
- Appointment of Nominated Adviser and Broker
- AGM research and development update highlights progress in both SCIB1 clinical trial and Moditope® platform
- Scancell to Present at the 14th Annual Biotech in Europe Forum
- Notice of AGM
- Scancell to Present at Upcoming Scientific Conferences
- Final Results for the year ended 30 April 2014
- Synergy of SCIB1 with checkpoint inhibitors
- Grant of Options to Director
- DNA ImmunoBody® Patent Granted in United States
- Update on Phase 1/2 clinical trial of SCIB1 in Stage III/IV melanoma
- Scancell to present latest SCIB1 data at ASCO Annual Meeting
- Directorate Change
- Dr Sally Adams to Join Scancell
- AACR Presentation on SCIB1
- 8mg Higher Dose SCIB1 Study On Track
- Publication of Moditope® Patent
- SCIB1 Granted FDA Orphan Drug Status
- Holdings in Company - 10 February 2014
- Nottingham Technology Grant
- DNA ImmunoBody® Patent Granted in Japan
- Grant of Options to Directors
- New Data for SCIBI in metastatic melanoma
- Unaudited interim results for 6 months ending 31st October 2013
- Extension to Ichor Commercial Option and Issue of Equity
- Results of AGM Nov 2013
- Director Share Dealing
- AGM Notice
- Investor update showcases Moditope® platform and updates SCIB1 trial progress
- Holdings in Company - 11 October 2013
- DNA IB Patent in Australia
- Holdings in Company
- Notification of Major Interest in Shares
- Result of General Meeting
- Result of Open Offer
- Director Shareholdings
- SCIB1 8mg Study Update
- Final Results for the year ended 30 April 2013
- Proposed Firm Placing and Open Offer and Notice of General Meeting
- Appoints Peter Allen as Non-Executive Director
- Resignation of Director
- ImmunoBody® Patent Approved for Grant in Japan
- Update on patient recruitment in the ongoing SCIB1 clinical trial
- SCIB1 Trial Update - Higher does allowed in phase 1/2 trial - 12th Dec 12
- Directorate Change 12 December 2012
- Update on SCIB1 Phase 1/2 clinical trial
- Result of AGM - 7 November 2012
- Annual Report 30 April 2012
- Notice of Results and Share Price Movement
- Holdings in Company - 6 October 2012
- Holdings in Company - 5 October 2012
- Change of Advisors
- Holdings in Company - 10 September 2012
- Holdings in Company - 3 September 2012
- Holdings in Company - 23 August 2012
- Holdings in Company - 20 August 2012
- Stimulation of killer CD4 T cells with potent anti-tumour activity
- SCIB1 Trial Update - Approval to dose patients for up to 5 years
- Vesting of Ichor Options
- SCIB1: First patient treated in Phase II clinical trial
- SCIB1 Trial Update
- Holdings in Company - 16 April 2012
- Investor presentation 2012
- ImmunoBody® Patent Approved in US
- Change of Registered office 29 February 2012
- Interim Results for the six month period to 31 October 2011
- Issue of Equity
- Helium Special Situations increases interest in Scancell
- Confirmation of second tranche payment of £2.85 million from Arana Therapeutics
- Progress on possible second tranche payment from Arana Therapeutics
- SCIB1 : Patent Awarded
- Holdings in Company - 19 August 2011
- Appointment of Director
- SCIB1: Safety Review and Dose Escalation
- Result of AGM and General Meeting
- Final Results for the Year Ended 30 April 2011
- Subdivision of share capital and Placing to raise £1.73 million
- Change of Board Structure
- Scancell develops new vaccine for the treatment of lung cancer
- Appointment of Broker
- Unaudited Interim Results for the six month period to 31st October 2010
- SCIB1: Safety Review and Dose Escalation January 2011
- Re: SCIB1 Clinical Trial Patient Recruitment
- Issue of Equity - 13 January 2011
- Result of AGM
- AGM Statement
- Appointment of Broker September 2010
- Collaboration With ImmuneRegen BioSciences® Yields Positive Results in Cancer Vaccine Studies
- Antibody Licence Agreement with Cancer Research Technology
- Withdrawal from PLUS and Admission to AIM
- Grant of Options
- Final Results for the year ended 30 April 2010
- Research collaboration with immatics to develop novel ImmunoBody® vaccines for colorectal cancer
- SCIB1 Phase I Trial Commences - First Patient Treated
- Scancell Enters Strategic Collaboration with ImmuneRegen BioSciences®
- ICHOR Medical Systems, Inc Quantification of Share Options under License and Supply Agreement
- National Institutes of Health Licensing Agreement
- Clinical Trial Approval for SCIB1 melanoma vaccine study
- Placing
- Placing of New Ordinary Shares
- Result of Open Offer - March 2010
- Director’s Dealings
- Open Offer
- Clinical Trial Application for SCIB1 melanoma vaccine
- Interim Results for the six month period to 31 October 2009
- Scancell Selects PharmaNet Development Group for SCIB1 Clinical Trial
- Completion of GMP manufacture for Scancell’s SCIB1 Clinical Trial
- Result of AGM - November 2009
- Preliminary Results for the Year Ended 30 April 2009
- Scancell Partners With ImmunoVaccine Technologies to Advance DNA Vaccine Delivery
- Scancell licenses TriGrid™ electroporation device from Ichor Medical Systems
- Scancell licenses key ImmunoBody® patents from Merck Serono
- Change of Advisor - July 2009
- Scancell Receives GBP250,000 emda Grant
- GMP Manufacture Deal With Cobra
- Interim Results for the six month period to 31 October 2008
- Issue of Equity - December 2008
- Notice of Results
- Admission to PLUS and Start of Trading
- Audited Final Results for the Year Ended
- AACR Presentation on Moditope®
- ASCO Release
- asco data release
- Patient recruitment completed for SCIB1 Phase 1/2 clinical trial
- Scancell and ImmunID announce collaboration to predict SCIB1 responders using ImmunTraCkeR®
- ImmunoBody Presentation at Cancer vaccines Conference in London
- Final Results for the year ended 30th April 2015
- PIVAC Conference Presentations
- Scancell strengthens operational and clinical development expertise
- AGM Business and R&D Update
- Scancell to conduct Phase II checkpoint inhibitor combination study with SCIB1 with leading US melanoma specialists
- Key Moditope® paper published in Cancer Research
- Directorate Change 2016
- Early Immune Effect of SCIB1 Cancer Vaccine Observed in Blood by ImmunTraCkeR® Companion Diagnostic
- Interim Results 31st October 2015
- Scancell to present at the Biotech Capital Conference
- Placing and Open Offer
- Placing and Open Offer Close
- Collaboration with Karolinska
- Posting of Circular
- Result of the Open Offer
- Result of the open offer 2
- Notification of Major Interest in Shares 2
- Notification of Major Interest in Shares
- Amendment to Options
- SCIB1 Drug Product Supply
- SCIB1 continues to deliver compelling survival data in melanoma
- Publication highlights advantages of Moditope technology platform
- Extension to Ichor Commercial Option
- Appointment of Eurogentec as SCIB1 manufacturer
- Dr Alan J. Lewis appointed as Non-Executive Director
- Final Results for the year ended 30 April 2016
- Scancell preparing SCIB2 for clinical study in lung cancer
- Results of AGM 2016
- Scancell to present at the World Immunotherapy Congress in Basel and at the Biotech and Money Inv€$tival Showcase in London
- SCIB1 Clinical Study Report
- ALCMI - Scancell Collaboration in Lung Cancer
- Scancell to present at the Immuno-Oncology Summit Europe 2017
- Placing raises £5.0 million, Issue of Equity and PDMR shareholding
- Proposed placing to raise up to £5.0 million
- Continued progress on SCIB1 - eight patients reach 5 year survival milestone
- Holdings in Company 01 March 2017
- Holdings in company 19 May 2017
- Holdngs in Company 19 May 2017 (II)
- Holdings in Company 22 May 2017
- Notice of AGM - Amendment
- Research Update - Amendment
- Interim Results January 2017
- Change of Registered Office April 2017
- Oncimmune and Scancell Present Data
- Scancell presents Moditope at International Cancer Immunotherapy Conference 2017
- Final Results for the year ended 30 April 2017
- Archived Webcasts and Interviews
-
News
- Latest News
- Webcasts, Interviews and Media Coverage
-
Regulatory news
- Interim Results for the six months ended 31 October 2014
- Scancell to provide positive SCIB1 Phase 1/2 clinical trial update during corporate presentations
- Holdings in Company - 15th December 2014
- Change of Registered Office
- Results of AGM
- Appointment of Nominated Adviser and Broker
- AGM research and development update highlights progress in both SCIB1 clinical trial and Moditope® platform
- Scancell to Present at the 14th Annual Biotech in Europe Forum
- Notice of AGM
- Scancell to Present at Upcoming Scientific Conferences
- Final Results for the year ended 30 April 2014
- Synergy of SCIB1 with checkpoint inhibitors
- Grant of Options to Director
- DNA ImmunoBody® Patent Granted in United States
- Update on Phase 1/2 clinical trial of SCIB1 in Stage III/IV melanoma
- Scancell to present latest SCIB1 data at ASCO Annual Meeting
- Directorate Change
- Dr Sally Adams to Join Scancell
- AACR Presentation on SCIB1
- 8mg Higher Dose SCIB1 Study On Track
- Publication of Moditope® Patent
- SCIB1 Granted FDA Orphan Drug Status
- Holdings in Company - 10 February 2014
- Nottingham Technology Grant
- DNA ImmunoBody® Patent Granted in Japan
- Grant of Options to Directors
- New Data for SCIBI in metastatic melanoma
- Unaudited interim results for 6 months ending 31st October 2013
- Extension to Ichor Commercial Option and Issue of Equity
- Results of AGM Nov 2013
- Director Share Dealing
- AGM Notice
- Investor update showcases Moditope® platform and updates SCIB1 trial progress
- Holdings in Company - 11 October 2013
- DNA IB Patent in Australia
- Holdings in Company
- Notification of Major Interest in Shares
- Result of General Meeting
- Result of Open Offer
- Director Shareholdings
- SCIB1 8mg Study Update
- Final Results for the year ended 30 April 2013
- Proposed Firm Placing and Open Offer and Notice of General Meeting
- Appoints Peter Allen as Non-Executive Director
- Resignation of Director
- ImmunoBody® Patent Approved for Grant in Japan
- Update on patient recruitment in the ongoing SCIB1 clinical trial
- SCIB1 Trial Update - Higher does allowed in phase 1/2 trial - 12th Dec 12
- Directorate Change 12 December 2012
- Update on SCIB1 Phase 1/2 clinical trial
- Result of AGM - 7 November 2012
- Annual Report 30 April 2012
- Notice of Results and Share Price Movement
- Holdings in Company - 6 October 2012
- Holdings in Company - 5 October 2012
- Change of Advisors
- Holdings in Company - 10 September 2012
- Holdings in Company - 3 September 2012
- Holdings in Company - 23 August 2012
- Holdings in Company - 20 August 2012
- Stimulation of killer CD4 T cells with potent anti-tumour activity
- SCIB1 Trial Update - Approval to dose patients for up to 5 years
- Vesting of Ichor Options
- SCIB1: First patient treated in Phase II clinical trial
- SCIB1 Trial Update
- Holdings in Company - 16 April 2012
- Investor presentation 2012
- ImmunoBody® Patent Approved in US
- Change of Registered office 29 February 2012
- Interim Results for the six month period to 31 October 2011
- Issue of Equity
- Helium Special Situations increases interest in Scancell
- Confirmation of second tranche payment of £2.85 million from Arana Therapeutics
- Progress on possible second tranche payment from Arana Therapeutics
- SCIB1 : Patent Awarded
- Holdings in Company - 19 August 2011
- Appointment of Director
- SCIB1: Safety Review and Dose Escalation
- Result of AGM and General Meeting
- Final Results for the Year Ended 30 April 2011
- Subdivision of share capital and Placing to raise £1.73 million
- Change of Board Structure
- Scancell develops new vaccine for the treatment of lung cancer
- Appointment of Broker
- Unaudited Interim Results for the six month period to 31st October 2010
- SCIB1: Safety Review and Dose Escalation January 2011
- Re: SCIB1 Clinical Trial Patient Recruitment
- Issue of Equity - 13 January 2011
- Result of AGM
- AGM Statement
- Appointment of Broker September 2010
- Collaboration With ImmuneRegen BioSciences® Yields Positive Results in Cancer Vaccine Studies
- Antibody Licence Agreement with Cancer Research Technology
- Withdrawal from PLUS and Admission to AIM
- Grant of Options
- Final Results for the year ended 30 April 2010
- Research collaboration with immatics to develop novel ImmunoBody® vaccines for colorectal cancer
- SCIB1 Phase I Trial Commences - First Patient Treated
- Scancell Enters Strategic Collaboration with ImmuneRegen BioSciences®
- ICHOR Medical Systems, Inc Quantification of Share Options under License and Supply Agreement
- National Institutes of Health Licensing Agreement
- Clinical Trial Approval for SCIB1 melanoma vaccine study
- Placing
- Placing of New Ordinary Shares
- Result of Open Offer - March 2010
- Director’s Dealings
- Open Offer
- Clinical Trial Application for SCIB1 melanoma vaccine
- Interim Results for the six month period to 31 October 2009
- Scancell Selects PharmaNet Development Group for SCIB1 Clinical Trial
- Completion of GMP manufacture for Scancell’s SCIB1 Clinical Trial
- Result of AGM - November 2009
- Preliminary Results for the Year Ended 30 April 2009
- Scancell Partners With ImmunoVaccine Technologies to Advance DNA Vaccine Delivery
- Scancell licenses TriGrid™ electroporation device from Ichor Medical Systems
- Scancell licenses key ImmunoBody® patents from Merck Serono
- Change of Advisor - July 2009
- Scancell Receives GBP250,000 emda Grant
- GMP Manufacture Deal With Cobra
- Interim Results for the six month period to 31 October 2008
- Issue of Equity - December 2008
- Notice of Results
- Admission to PLUS and Start of Trading
- Audited Final Results for the Year Ended
- AACR Presentation on Moditope®
- ASCO Release
- asco data release
- Patient recruitment completed for SCIB1 Phase 1/2 clinical trial
- Scancell and ImmunID announce collaboration to predict SCIB1 responders using ImmunTraCkeR®
- ImmunoBody Presentation at Cancer vaccines Conference in London
- Final Results for the year ended 30th April 2015
- PIVAC Conference Presentations
- Scancell strengthens operational and clinical development expertise
- AGM Business and R&D Update
- Scancell to conduct Phase II checkpoint inhibitor combination study with SCIB1 with leading US melanoma specialists
- Key Moditope® paper published in Cancer Research
- Directorate Change 2016
- Early Immune Effect of SCIB1 Cancer Vaccine Observed in Blood by ImmunTraCkeR® Companion Diagnostic
- Interim Results 31st October 2015
- Scancell to present at the Biotech Capital Conference
- Placing and Open Offer
- Placing and Open Offer Close
- Collaboration with Karolinska
- Posting of Circular
- Result of the Open Offer
- Result of the open offer 2
- Notification of Major Interest in Shares 2
- Notification of Major Interest in Shares
- Amendment to Options
- SCIB1 Drug Product Supply
- SCIB1 continues to deliver compelling survival data in melanoma
- Publication highlights advantages of Moditope technology platform
- Extension to Ichor Commercial Option
- Appointment of Eurogentec as SCIB1 manufacturer
- Dr Alan J. Lewis appointed as Non-Executive Director
- Final Results for the year ended 30 April 2016
- Scancell preparing SCIB2 for clinical study in lung cancer
- Results of AGM 2016
- Scancell to present at the World Immunotherapy Congress in Basel and at the Biotech and Money Inv€$tival Showcase in London
- SCIB1 Clinical Study Report
- ALCMI - Scancell Collaboration in Lung Cancer
- Scancell to present at the Immuno-Oncology Summit Europe 2017
- Placing raises £5.0 million, Issue of Equity and PDMR shareholding
- Proposed placing to raise up to £5.0 million
- Continued progress on SCIB1 - eight patients reach 5 year survival milestone
- Holdings in Company 01 March 2017
- Holdings in company 19 May 2017
- Holdngs in Company 19 May 2017 (II)
- Holdings in Company 22 May 2017
- Notice of AGM - Amendment
- Research Update - Amendment
- Interim Results January 2017
- Change of Registered Office April 2017
- Oncimmune and Scancell Present Data
- Scancell presents Moditope at International Cancer Immunotherapy Conference 2017
- Final Results for the year ended 30 April 2017
- Archived Webcasts and Interviews
Press coverage
- What I Learned From the CEO of an Immunotherapy Start-Up
- Biotech blockbusters
- Is this the pioneering DNA vaccine we've been waiting for?
- Electric jab in your arm that fights skin cancer
- Finanz und Wirtschaft 5th June 2013
- Finanz und Wirtschaft 12th June 2013
- ECOreporter 14th August 2013
- Scancell And OncoSec looking good with melanoma immunotherapies
- Why checkpoint inhibitors need help June 2014
Webcasts, Interviews and Media Coverage
Scancell recruits deal maker to take over as CEO
Executive chairman John Chiplin said new CEO Dr Cliff Holloway's extensive experience and accomplishments speak volumes
Tue, 10 Oct 2017 08:24:00
Scancell on the lookout for partners after year of “significant progress”
“We are continuing to explore a number of funding options to ensure that we have the resources to progress these programmes through their next phase”
Wed, 13 Sep 2017 06:21:00
Scancell presents Moditope data at prestigious cancer conference
Chief scientific officer Lindy Durrant presented two posters at the International Cancer Immunotherapy conference in Germany on Friday
Mon, 11 Sep 2017 09:25:00
News updates
Sign up to our newsletter to stay up to date with Scancell
Privacy & legal notes
© Copyright Scancell Limited 2017
A site by The Unified Theory